BIM
ACHN

Bogle Investment Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Bogle Investment Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-273,405
Closed -$1.25M – 386
2017
Q2 		$1.25M Buy
273,405
+26,448
+11% +$106K 0.09% 181
2017
Q1 		$1.04M Sell
246,957
-45,476
-16% -$189K 0.07% 219
2016
Q4 		$1.21M Buy
+292,433
New +$1.55M 0.08% 235
2015
Q1 		– Sell
-25,700
Closed -$314K – 448
2014
Q4 		$314K Buy
+25,700
New +$314K 0.02% 317

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Bogle Investment Management's ACHN Position: Q3 2017 in Review

Bogle Investment Management sold out of Achillion Pharmaceuticals (ACHN) in Q3 2017, closing a stake of 273,405 shares — an estimated $1.25M sold.

Bogle Investment Management first reported a position in ACHN in Q4 2014 and held it in 4 quarters. The position peaked at $1.25M in Q2 2017. 125 funds tracked by Wall St. Rank hold ACHN as of Q3 2017.

  • Bogle Investment Management reported no remaining Achillion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Bogle Investment Management sold 273,405 Achillion Pharmaceuticals shares in Q3 2017, an estimated $1.25M.
  • Bogle Investment Management first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 4 quarters.
  • Bogle Investment Management's Achillion Pharmaceuticals position peaked at $1.25M in Q2 2017.
  • 125 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2017.

Based on Bogle Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.